仲裁庭确认Prime Medicine拥有开发和商业化Pm647用于AATD的权利

美股速递
Jul 08

仲裁庭已正式确认,Prime Medicine, Inc. 拥有开发和商业化其候选药物Pm647用于治疗α-1抗胰蛋白酶缺乏症(AATD)的权利。这一决定解决了围绕该药物权益的潜在争议,为该公司推进该治疗项目扫清了关键的法律障碍。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10